IGM Biosciences amends bylaws to update proxy, stockholder meeting procedures

IGM Biosciences, Inc.

Bylaws amended effective March 16, 2023 to align with universal proxy rules and DGCL changes.
Updated advance notice procedures for director nominations and stockholder proposals, including Rule 14a-19 compliance.
Requires additional disclosures on related party transactions and third-party compensation for director nominees.
Board gains explicit authority to cancel, postpone, or reschedule annual and special stockholder meetings.
Changes conform to recent amendments to the Delaware General Corporation Law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IGM Biosciences, Inc.: Adopted amended and restated bylaws updating advance notice procedures, board actions, and meeting procedures to reflect universal proxy rules and DGCL amendments (effective 2023-03-16).

Change: bylaw amendment
Effective: 2023-03-16

Exact text from the filing

On March 16, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of IGM Biosciences, Inc. (the “Company”) the Company’s board of directors (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0000950170-23-008939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.